Ipsen liver disease drugs endorsed in EU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 26 2024
0mins
Source: SeekingAlpha
Ipsen's Drug Approvals: French drugmaker Ipsen received positive recommendations from the European Medicines Agency for two liver-targeting drugs: Iqirvo for primary biliary cholangitis and Kayfanda for cholestatic pruritus in Alagille syndrome.
Next Steps for Authorization: The recommendations from the EMA’s Committee for Medicinal Products for Human Use will be reviewed by the European Commission, with final decisions expected in Q3 2024.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
